All In Biotech

Drug Trial Radar · NCT02452424

A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors

Phase 1/2a Study of Double-Immune Suppression Blockade By Combining a CSF1R Inhibitor (PLX3397) With An Anti-PD-1 Antibody (Pembrolizumab) To Treat Advanced Melanoma And Other Solid Tumors

Last checked: Nov 20, 2026Latest source record: Mar 5, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registry

Status

Terminated

Enrollment

78

Actual

Start

Jul 2, 2015

Primary completion

Aug 17, 2018

Study completion Oct 12, 2018

Sponsor

Lead sponsor
Daiichi SankyoDaiichi Sankyo (DSNKY)
Sponsor type
Industry
Collaborators
Plexxikon; Merck Sharp & Dohme LLC
First posted
May 22, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical research study is to learn how PLX3397 and pembrolizumab work together to affect cancer cells. PLX3397 is designed to target the receptor for CSF1 (CSF1R). Pembrolizumab is designed to block the interaction between the receptor PD-1 and molecules that bind PD-1. In this study, PLX3397 and pembrolizumab are being given together in order to study their combined effects on patients' immune responses to their tumors. Tumor-specific immune responses have been shown to kill cancer cells and/or to stop tumors from growing. Part 1 of the study (dose-escalation phase) will establish the safest dose of PLX3397 to be given in combination with pembrolizumab. Part 2 of the study (expansion phase) will include an evaluation of efficacy of this combination in the following tumor types: * Advanced melanoma: prior anti-PD-1/PD-L1 therapy but never responded * Advanced melanoma: prior anti-PD-1/PD-L1 therapy and responded but later progressed as defined by irRECIST while on therapy * Non-small cell lung cancer * Ovarian cancer * Gastrointestinal Stromal Tumor (GIST) * Squamous cell cancer of the head and neck

Conditions

  • Melanoma
  • Non-small Cell Lung Cancer
  • Squamous Cell Carcinoma of the Head and Neck
  • Gastrointestinal Stromal Tumor (GIST)
  • Ovarian Cancer

Interventions

  • PLX3397Drug

    PLX3397 capsules, 200 mg

  • PembrolizumabBiological

    Pembrolizumab, 200 mg, IV

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Treatment-emergent Adverse Events (TEAEs) in Participants Regardless of Causality While Taking PLX3397 in Combination With PembrolizumabTime frame: 1 year (Dose Escalation); 2 years (Dose Expansion)

Locations

12 sites in 1 country. Site status is shown where the registry gives one.

  • HonorHealth Research Institute

    Scottsdale, Arizona

  • Marin Cancer Care

    Greenbrae, California

  • Ronald Reagan UCLA Medical Center

    Los Angeles, California

  • Massachusetts General Hospital

    Boston, Massachusetts

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts

  • Dana-Farber Cancer Institute

    Boston, Massachusetts

  • Karmanos Cancer Institute

    Detroit, Michigan

  • Washington University St. Louis Siteman Cancer Center

    St Louis, Missouri

  • Memorial Sloan Kettering Cancer Center

    New York, New York

  • Medical University Health Hollings Cancer Center

    Charleston, South Carolina

  • Vanderbilt Ingram Cancer Center

    Nashville, Tennessee

  • South Texas Accelerated Research Therapeutics

    San Antonio, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.